Protein & Cell >

2017 , Vol. 8 >Issue 4: 296 - 301

DOI: https://doi.org/10.1007/s13238-016-0356-4

LETTER

PML-RARA mutations confer varying arsenic trioxide resistance

  • Dong-Mei Bai 1,2 ,
  • Xiao-Feng Zheng , 1,2
Expand
  • 1. State Key Lab of Protein and Plant Gene Research, Beijing 100871, China
  • 2. Department of Biochemistry and Molecular Biology, School of Life Sciences, Peking University, Beijing 100871, China

Published date: 19 May 2017

Copyright

2016 The Author(s) 2016. This article is published with open access at Springerlink.com and journal.hep.com.cn
Fold

Cite this article

Dong-Mei Bai , Xiao-Feng Zheng . PML-RARA mutations confer varying arsenic trioxide resistance[J]. Protein & Cell, 2017 , 8(4) : 296 -301 . DOI: 10.1007/s13238-016-0356-4

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
deThe H, ChomienneC, LanotteM, DegosL, DejeanA (1990) The t (15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus.Nature347:558–561

DOI

2
GotoE, TomitaA, HayakawaF, AtsumiA, KiyoiH, NaoeT (2011) Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.Blood118:1600–1609

DOI

3
JeanneM, Lallemand-BreitenbachV, FerhiO, KokenM, Le BrasM, DuffortS, PeresL, BerthierC, SoilihiH, RaughtB (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.Cancer Cell18:88–98

DOI

4
Lallemand-BreitenbachV, ZhuJ, PuvionF, KokenM, HonoreN, DoubeikovskyA, DuprezE, PandolfiPP, PuvionE, FreemontP (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.J Exp Med193:1361–1371

DOI

5
Lallemand-BreitenbachV, JeanneM, BenhendaS, NasrR, LeiM, PeresL, ZhouJ, ZhuJ, RaughtB, deThe H (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.Nat Cell Biol10:547–555

DOI

6
LiJ, ChenP, SinogeevaN, GorospeM, WerstoRP, ChrestFJ, BarnesJ, LiuY (2002) Arsenic trioxide promotes histone H3 phosphoacetylation at the chromatin of CASPASE-10 in acute promyelocytic leukemia cells.J Biol Chem277:49504–49510

DOI

7
LiuJ, ZhuHH, JiangH, JiangQ, HuangXJ (2016) Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.Blood127:243–250

DOI

8
Lo-CocoF, AvvisatiG, VignettiM, ThiedeC, OrlandoSM, IacobelliS, FerraraF, FaziP, CicconiL, Di BonaE (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.N Engl J Med369:111–121

DOI

9
RiceKL, deThe H (2014) The acute promyelocytic leukaemia success story: curing leukaemia through targeted therapies.J Intern Med276:61–70

DOI

10
WangZY, ChenZ (2008) Acute promyelocytic leukemia: from highly fatal to highly curable.Blood111:2505–2515

DOI

11
ZhangXW, YanXJ, ZhouZR, YangFF, WuZY, SunHB, LiangWX, SongAX, Lallemand-BreitenbachV, JeanneM (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Science328:240–243

DOI

12
ZhouGB, ZhangJ, WangZY, ChenSJ, ChenZ (2007) Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.Philos Trans R Soc Lond B Biol Sci362:959–971

DOI

13
ZhuHH, HuangXJ (2014) Oral arsenic and retinoic acid for non-highrisk acute promyelocytic leukemia.N Engl J Med371:2239–2241

DOI

14
ZhuHH, QinYZ, HuangXJ (2014) Resistance to arsenic therapy in acute promyelocytic leukemia.N Engl J Med370:1864–1866

DOI

Options
Outlines

/

〈 〉